Genetic Technology--Life Science Trends across Drug Development for Central Nervous System Disorders

USD 250

* Required Fields

USD 250


Be the first to review this product

This edition of Genetic Technology depicts the current landscape and the new life sciences trends across schizophrenia and other central nervous system (CNS) disorders. Specific products developed to target chronic CNS disorders, including the use of cell therapeutics and autoimmune approaches, are profiled. Additionally, analyst insights and strategic perspectives for business development across neurological diseases are presented, along with the intellectual property scenario around therapeutics for CNS disorders.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Central nervous system (CNS), CNS disorders, cell therapeutics, immune system, stem cell platforms, schizophrenia

Table of Contents

Genetic Technology--Life Science Trends across Drug Development for Central Nervous System DisordersTrend-based Technology ProfilesTherapeutic Solutions for Schizophrenia and other CNS DisordersProducts Developed to Target Chronic CNS DisordersBoosting Patients’ Immune Systems to Develop Treatment for CNS DisordersUsing Stem Cell Platforms for Development of Treatments for CNS DisordersStrategic PerspectivesAnalyst Insights on Drug Developments for CNS DisordersAppendixPatent ScenarioPatent Scenario (continued)Industry Interactions




Related Research

Release Date : 29-Dec-17

Region : Global

Release Date : 29-Dec-17

Region : Global

Release Date : 31-Oct-17

Region : Global

Release Date : 19-May-17

Region : Global

Related Subscription

• One-2-One Analyst briefing call •
• Access to published and new research deliverables •
• Mid year service review •
• Virtual Analyst briefing •
• GIL conference seats •

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.